Showing results (341-350 of 419) with videos related to
Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.Med (New York, N.Y.)|June 28, 2025
Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancersSteven H Lin, Vivek Subbiah, Evan N Cohen, et al.Journal of Hematology & Oncology|June 12, 2015
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusionVivek Subbiah, Caitlin McMahon, Shreyaskumar Patel, et al.Cancer|October 20, 2015
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapiesRami N Al-Rohil, Ashley J Tarasen, J Andrew Carlson, et al.Cancer Discovery|October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationDavid S Hong, Van K Morris, Badi El Osta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East AfricaWalter O Mwanda, Jackson Orem, Pingfu Fu, et al.Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.NPJ Precision Oncology|March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) studyApostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.European Journal of Cancer (Oxford, England : 1990)|July 24, 2020
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trialsDario Pasalic, Gwendolyn J McGinnis, C David Fuller, et al.Pageof 42